NCT00032799View on ClinicalTrials.gov

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

905

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
Crohn's Disease
Interventions
DRUG

natalizumab

Trial Locations (1)

92121

Elan Pharmaceuticals, San Diego

Sponsors

Lead Sponsor

Biogen

Collaborators (1)

Elan Pharmaceuticals
All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Biogen

INDUSTRY